1. Home
  2. CKPT vs LXEO Comparison

CKPT vs LXEO Comparison

Compare CKPT & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CKPT
  • LXEO
  • Stock Information
  • Founded
  • CKPT 2014
  • LXEO 2017
  • Country
  • CKPT United States
  • LXEO United States
  • Employees
  • CKPT N/A
  • LXEO N/A
  • Industry
  • CKPT Biotechnology: Pharmaceutical Preparations
  • LXEO
  • Sector
  • CKPT Health Care
  • LXEO
  • Exchange
  • CKPT Nasdaq
  • LXEO Nasdaq
  • Market Cap
  • CKPT 172.4M
  • LXEO 140.6M
  • IPO Year
  • CKPT 2017
  • LXEO 2023
  • Fundamental
  • Price
  • CKPT $4.04
  • LXEO $3.13
  • Analyst Decision
  • CKPT Buy
  • LXEO Strong Buy
  • Analyst Count
  • CKPT 3
  • LXEO 5
  • Target Price
  • CKPT $4.33
  • LXEO $22.80
  • AVG Volume (30 Days)
  • CKPT 5.7M
  • LXEO 844.8K
  • Earning Date
  • CKPT 03-28-2025
  • LXEO 03-24-2025
  • Dividend Yield
  • CKPT N/A
  • LXEO N/A
  • EPS Growth
  • CKPT N/A
  • LXEO N/A
  • EPS
  • CKPT N/A
  • LXEO N/A
  • Revenue
  • CKPT $41,000.00
  • LXEO N/A
  • Revenue This Year
  • CKPT $102,182.93
  • LXEO N/A
  • Revenue Next Year
  • CKPT $351.71
  • LXEO N/A
  • P/E Ratio
  • CKPT N/A
  • LXEO N/A
  • Revenue Growth
  • CKPT N/A
  • LXEO N/A
  • 52 Week Low
  • CKPT $1.38
  • LXEO $2.32
  • 52 Week High
  • CKPT $4.50
  • LXEO $19.50
  • Technical
  • Relative Strength Index (RSI)
  • CKPT 65.90
  • LXEO 44.09
  • Support Level
  • CKPT $4.01
  • LXEO $3.75
  • Resistance Level
  • CKPT $4.07
  • LXEO $4.59
  • Average True Range (ATR)
  • CKPT 0.03
  • LXEO 0.51
  • MACD
  • CKPT -0.00
  • LXEO 0.11
  • Stochastic Oscillator
  • CKPT 70.00
  • LXEO 31.13

About CKPT Checkpoint Therapeutics Inc.

Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.

About LXEO Lexeo Therapeutics Inc.

Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.

Share on Social Networks: